Dr Reddy’s Laboratories will announce its Q2 FY26 results on October 25. Analysts expect a steady quarter led by India and Europe, while the US business continues to face headwinds from gRevlimid tapering and base portfolio erosion. Margins are expected to stay near the 25 percent mark, supported by mix improvement and currency tailwinds, even as pricing pressure weighs on profitability.

A Moneycontrol poll of four brokerages pegs revenue growth at 8 to 9 percent year-on-year to around Rs 8,650 to 8,750 crore, and net profit near Rs 1,450 crore, up 15 to 16 percent YoY. EBITDA is seen at Rs 2,150 to 2,200 crore, with margins of 24.5 to 25.8 percent, broadly stable sequentially.

Key factors driving Q2 earnings

Dr Reddy’s performance this quarter is expected to be regionally mixed. The

See Full Page